U.S. equities rose at midday on optimism the new tariffs threatened by President Trump won't be as severe as initially ...

Eva Ados, ERshares COO and chief investment strategist, joins CNBC's 'Power Lunch' to share outlooks on three stocks.

While the headline numbers don't inspire much confidence, Moderna is a stock that deserves a closer look. The company still ...

Key Takeaways Moderna received a $590 million award from the U.S. government to speed development of a vaccine that could be ...

Earlier this month, Moderna announced business updates and progress across its pipeline. Moderna says it enters 2025 with a ...

"We remain focused on our three strategic priorities: driving sales growth, delivering up to 10 product approvals over the ...

In addition to reporting 2024 revenue at the lower end of its previous guided range, Moderna issued a disappointing forward ...

Investing.com -- Moderna , Inc. (NASDAQ: MRNA) shares surged 14% following remarks by Oracle (NYSE: ORCL) Chairman Larry ...

Moderna Inc (MRNA) stock saw a modest uptick, ending the day at $38.5 which represents a slight increase of $2.61 or 7.27% from the prior close of $35.89. The stock opened at $36.35 and touched a low ...

Moderna shares will likely remain under scrutiny after plunging nearly 17% Monday as the embattled drug maker slashed its ...

Shares of Moderna plunged 20% Monday after the vaccine maker slashed its forecast of full-year 2025 revenue, as sales of its ...

Moderna now expects 2025 revenue to come in between $1.5 billion and $2.5 billion, most of which will come in the second half ...